Everyone experiences nosebleeds at some point, but nosebleeds with no known cause can be a sign of hemophilia, according to ...

Without enough of the clotting factor, people with hemophilia bleed longer than those without the disease. Their bodies are unable to effectively stop the flow of blood from wounds. Hemophilia B ...

Your blood contains proteins, called clotting factors, that help to control bleeding. Healthcare providers treat hemophilia by boosting clotting factor levels or replacing missing clotting factors.

BioMarin's Roctavian gene therapy shows long-term effectiveness in treating severe hemophilia A, reducing bleeding and ...

Hemophilia is a rare blood clotting disorder that can lead to prolonged bleeding after an injury or surgery, as well as spontaneous bleeding in the muscles, joints, or organs.

With HMB-001, Hemab aims to use blood clotting proteins already in the body to help improve platelet function. The drug is a bispecific antibody with one part designed to bind to and stabilize a ...

Hympavzi, made by Pfizer, is the first antitissue-factor pathway inhibitor to be approved for the blood-clotting disorder, as well as the first hemophilia drug to offer a once-weekly treatment ...

Hemophilia A patients already have a non-factor drug option—Hemlibra. That blockbuster Roche drug is an antibody designed to mimic the function of a clotting protein called factor VIII.

The Food and Drug Administration approved Roctavian for adult patients with severe cases of hemophilia A, the inherited blood-clotting disorder that can lead to bleeding after minor injuries or ...

WASHINGTON (AP) — U.S. health regulators on Tuesday approved the first gene therapy for hemophilia, a $3.5 million one-time treatment for the blood-clotting disorder. The Food and Drug ...

The FDA is also considering another hemophilia B gene therapy for approval in adults -- fidanacogene elaparvovec, which contains a bio-engineered adeno-associated virus capsid and a high-activity ...